NCT06519760Recruiting
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
Evaluation of Diagnostic Value of 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 7 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET/CT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1. Researchers will compare the diagnostic value of 68Ga-C1 PET/CT and 18F-FDG PET/CT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 17 Jul 2024
- Start date
- 30 Jul 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Peking University First Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT06519760
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 30 Jul 2024 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;
Other illness
- Have other malignancies that require treatment;
- Uncontrolled psychiatric disorders;
- Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).
Lab values
- Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²;
Other
- Renal mass is known to be a metastasis of another primary tumor;
- Pregnant and lactating women or female patients plan to become pregnant within 6 months;
Who the study is looking for
- Signed written informed consent；
- Age ≥18；
- Patients with confirmed or suspected clear cell renal cell carcinoma;
- Expected survival ≥6 months.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.